About this trial
This study will assess cognition, neural function, and drug exposure in chronic pain patients who have been prescribed medical cannabis and will differentiate outcomes based on use of specific CBD-dominant versus THC-dominant treatment products. This longitudinal study will recruit medical cannabis users from local dispensaries. Each participant will complete a baseline assessment prior to the start of medical cannabis use, monthly phone calls to assess treatment adherence, and a four-month follow- up assessment. The aims of this project are: Aim 1. To assess impacts of medical cannabis compounds on executive functions, learning and memory in adults to determine whether cognitive impairments are evident after the onset of cannabis use; Aim 2. To assess the impacts of medical cannabis compounds on white matter microstructure, functional brain activity and functional connectivity; Aim 3. To differentiate change over four months in these outcomes as a function of (a) age and (b) pre-to-post-treatment changes in blood levels of cannabinoid compounds.
Eligibility criteria
Qualifiers
Medical cannabis users (n=120) will be required to
Be ages 35-65;
Be qualified for a medical cannabis prescription based only on a diagnosis of chronic pain; note that individuals can, in theory, utilize medical cannabis for more than one qualifying condition. People with orthopedic pain will be prioritized.
Have normal or corrected-to-normal vision and hearing;
Disqualifiers
Cannot have a degenerative neurological condition or a neurological condition that impacts brain function (e.g., epilepsy);
No contraindications to MRI scanning;
No lifetime history of severe DSM-V psychopathology (psychotic disorders, bipolar disorder); if currently treated mood for anxiety disorders, must be stable;
No current pregnancy or pregnancy within the prior 3 months; cannot be lactating;
Trial design
Treatments tested in this trial
- Cognitive testing
- Task-based fMRI measure of inhibitory control
- Task-based fMRI measure of face-name learning
Treatment groups
Sponsors and collaborators
University of Minnesota
Lead sponsor
National Institute on Drug Abuse (NIDA)
Collaborator